Patents Assigned to Beth Israel Deaconess Medical Center
  • Patent number: 11027474
    Abstract: Systems, devices and methods are provided for fabricating anisotropic polymer materials. According to various embodiments, a fluidic device is employed to distribute a polymer solution and a flow-confining solution in order to generate a layered flow, where the layered flow is formed such that a polymer liquid sheet is sheathed on opposing sides by flow-confining liquid sheets. The fluidic device includes first and second fluid conduits, where the first fluid conduit receives the layered flow. The second fluid conduit has a reduced height relative to the first fluid conduit, such that the layered flow is constricted as it flows through the second fluid conduit. The constriction formed by the second flow conduit causes hydrodynamic focusing, reducing the thickness of the polymer liquid sheet, and inducing molecular alignment and anisotropy within the polymer liquid sheet as it is hardened and as strain is applied during extrusion of the sheet.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: June 8, 2021
    Assignees: Beth Israel Deaconess Medical Center Inc., The Governing Council of the University of Toronto
    Inventors: Lian Leng, Stephanie Grainger, Elliot L. Chaikof, Axel Guenther, David Miranda Nieves, Shashi Malladi, Richard Cheng
  • Patent number: 11026921
    Abstract: The present invention provides compositions and methods for treating cancer.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 8, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center
    Inventors: David Avigan, Jacalyn Rosenblatt, Donald Kufe
  • Patent number: 11013711
    Abstract: Provided herein are methods for treating type 1 diabetes and its sequelae (e.g., cardiovascular, renal or neurologic diseases for which type 1 diabetes is a risk factor) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a fatty acid ester of a hydroxy fatty acid (FAHFA), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: May 25, 2021
    Assignees: Beth Israel Deaconess Medical Center, Inc., Salk Institute for Biological Studies, President and Fellows of Harvard College
    Inventors: Barbara B. Kahn, Alan Saghatelian, Ismail Syed
  • Publication number: 20210147390
    Abstract: Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X1-X4, RX, RC, RB, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases.
    Type: Application
    Filed: April 5, 2019
    Publication date: May 20, 2021
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Elliot Chaikof, Lijun Sun
  • Patent number: 11008620
    Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 18, 2021
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center
    Inventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
  • Patent number: 11001562
    Abstract: The instant invention provides near-infrared fluorescent nerve contrast agents and methods of using them.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: May 11, 2021
    Assignees: Beth Israel Deaconess Medical Center, Georgia State University Research Foundation Inc.
    Inventors: John V. Frangioni, Hak Soo Choi, Maged M. Henary
  • Patent number: 10980835
    Abstract: The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 20, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou
  • Patent number: 10982000
    Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: April 20, 2021
    Assignees: Novartis AG, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Anthony Rosenzweig, Jason D. Roh, David J. Glass
  • Patent number: 10973431
    Abstract: Electrical impedance myography (EIM) can be used for assessment and diagnosis of muscular disorders. EIM includes applying an electrical signal to a region of tissue and measuring a resulting signal. A characteristic of the region of tissue is determined based on the measurement. Performing EIM at different frequencies and modeling one or more impedance metrics as a function of frequency may provide impedance model parameters that can aid in the assessment and diagnosis. Devices are described that facilitate assessment and diagnosis using EIM.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: April 13, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Seward B. Rutkove, Benjamin Sanchez Terrones
  • Patent number: 10947597
    Abstract: The invention features compositions and methods for detecting and quantifying BRAFV600E in a sample of a subject. In particular embodiments, the invention provides a highly sensitive and precise quantitative method for diagnosis, post-operative surveillance, and monitoring evidence of disease over time in the adjuvant setting (i.e. treatment with BRAF-inhibitors).
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: March 16, 2021
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventor: David J. Panka
  • Patent number: 10945658
    Abstract: In some embodiments, there is provide a method of analysing a bone fracture, comprising; stabilizing a bone having a fracture including a first support point located distal of the fracture and a second support point located proximal of the fracture; applying a force to an area of the bone having the fracture to cause a displacement of the fracture; imaging the bone during the application of force thereto; and comparing the image of the bone during the application of force to an image of the bone without the application of force to determine the state of the fracture.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: March 16, 2021
    Assignees: Worcester Polytechnic Institute, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Karen L. Troy, John J. Wixted, Ara Nazarian
  • Patent number: 10940151
    Abstract: The invention features methods for treating or reducing the likelihood of developing a renal disease by administering to a subject in need thereof an agent that decreases expression of a pathogenic APOL1. The agents of the method target various signaling pathways and decrease the level of the pathogenic APOL1 polypeptide.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 9, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: David J. Friedman, Martin R. Pollak
  • Patent number: 10941399
    Abstract: The present invention relates to chimeric RNA oligonucleotides that are single-stranded oligonucleotides. These compounds are capable of targeting particular genes and reducing DNA methyltransferase activity. Accordingly, these compounds are particularly useful in the treatment of disease associated with aberrant DNA methyltransferase activity, such as cancer or a genetic disorder.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: March 9, 2021
    Assignees: Beth Israel Deaconess Medical Center, Inc., Università Cattolica del Sacro Cuore
    Inventors: Annalisa Di Ruscio, Alexander K. Ebralidze, Daniel G. Tenen, Giuseppe Leone
  • Publication number: 20210059551
    Abstract: A method and system for high-throughput detection of coronary artery stenosis observes trends in abnormal or pathologic morphology of the electrocardiogram (ECG). A first set of ECG signals is monitored from a patient. A baseline measurement is generated from the monitored first set of ECG signals to contain nonpathologic ECG morphologies in each lead. A second set of ECG signals is monitored from the patient and a second mean measurement during or after stress is generated from the second set of ECG signals. A residuum signal is generated for each lead based on the baseline measurement and the second mean measurement. The residuum signals are averaged across the leads for each timepoint. T-wave heterogeneity is quantified based on the generated residuum signals and the averaged residuum signal at each timepoint, and used to detect coronary artery stenosis.
    Type: Application
    Filed: March 8, 2019
    Publication date: March 4, 2021
    Applicant: Beth Israel Deaconess Medical Center,
    Inventors: Bruce D. NEARING, Richard L. VERRIER
  • Publication number: 20210052598
    Abstract: The present disclosure features compositions and methods of treating a cancer in a subject by administering to the subject a Skp2 inhibitor and an inhibitor of glycolytic metabolism (e.g., PKM2 inhibitor).
    Type: Application
    Filed: March 6, 2019
    Publication date: February 25, 2021
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Wenyi Wei
  • Patent number: 10928404
    Abstract: Magnetic cell levitation and cell monitoring systems and methods are disclosed. A method for separating a heterogeneous population of cells is performed by placing a microcapillary channel containing the heterogeneous population of cells in a magnetically-responsive medium in the disclosed levitation system and separating the cells by balancing magnetic and corrected gravitational forces on the individual cells. A levitation system is also disclosed, having a microscope on which the microcapillary channel is placed and a set of two magnets between which the microcapillary channel is placed. Additionally, a method for monitoring cellular processes in real-time using the levitation system is disclosed.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: February 23, 2021
    Assignees: The Brigham and Women's Hospital, Inc., The Board of Trustees of the Leland Stanford Junior University, Beth Israel Deaconess Medical Center
    Inventors: Utkan Demirci, Ionita Ghiran, Savas Tasoglu, Ronald W. Davis, Lars Steinmetz, Naside Gozde Durmus, Huseyin Cumhur Tekin
  • Patent number: 10906962
    Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: February 2, 2021
    Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
  • Patent number: 10898100
    Abstract: Electrical impedance myography (EIM) can be used for the assessment and diagnosis of muscular disorders. EIM includes applying an electrical signal to a region of tissue and measuring a resulting signal. A characteristic of the region of tissue is determined based on the measurement. Performing EIM at different frequencies and/or different angular orientations with respect to a muscle can aid in the assessment and diagnosis. Devices are described that facilitate assessment and diagnosis using EIM.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: January 26, 2021
    Assignees: Beth Israel Deaconess Medical Center, Inc., Northeastern University
    Inventors: Seward B. Rutkove, Carl A. Shiffman, Ronald Aaron
  • Publication number: 20210002649
    Abstract: The invention generally provides a method of treating cancer, the method comprising administering to a subject having a cancer, an effective amount of an agent that inhibits the expression or activity of WW domain-containing protein-1 (WWP1) in combination with anti-PD-1 and/or anti-PD-L1 monoclonal antibodies.
    Type: Application
    Filed: February 28, 2019
    Publication date: January 7, 2021
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Wenyi Wei, Pier Paolo Pandolfi, Yu Ru Lee
  • Patent number: 10884001
    Abstract: Featured are methods of diagnosing and treating liver disease.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: January 5, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Detlef Schuppan, Towia Libermann, Simon T. Dillon, Yury Papou